Pramlintide improves glucose control in type 1 diabetes

July 25, 2012
Pramlintide improves glucose control in type 1 diabetes
The addition of pramlintide, an analog of the naturally-occurring β-cell peptide amylin, before meals improves blood glucose control in patients with type 1 diabetes receiving insulin through an external closed-loop artificial pancreas system, according to a study published online June 18 in Diabetes Care.

(HealthDay) -- The addition of pramlintide, an analog of the naturally-occurring β-cell peptide amylin, before meals improves blood glucose control in patients with type 1 diabetes receiving insulin through an external closed-loop artificial pancreas system, according to a study published online June 18 in Diabetes Care.

To examine whether preprandial injections of pramlintide would improve postprandial glycemia by delaying gastric emptying, Stuart A. Weinzimer, M.D., from the Yale University School of Medicine in New Haven, Conn., and colleagues treated eight patients with type 1 diabetes (15 to 30 years old) with a closed-loop delivery system for 24 hours either alone or plus preprandial injections of 30 µg pramlintide.

The researchers found that the addition of pramlintide significantly increased the mean time to peak (2.5 versus 1.5 hours). The addition of pramlintide also significantly reduced the mean magnitude of glycemic excursion (88 versus 113 mg/dL), with the reduction being particularly pronounced at lunch and dinner, when premeal insulin concentrations were higher.

"Pramlintide delayed the time to peak postprandial blood glucose and reduced the magnitude of prandial blood glucose excursions," Weinzimer and colleagues conclude. "Beneficial effects of pramlintide on closed-loop may in part be related to higher premeal insulin levels at lunch and dinner compared with breakfast."

Two authors are employees of Medtronic , which provided equipment for the study. Two additional authors are consultants/advisors to Medtronic MiniMed and Animas Corporation.

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

ADA: Hypo-hyperglycemia minimizer system feasible

June 12, 2012

(HealthDay) -- The hypoglycemia-hyperglycemia minimizer (HHM) system, which includes a continuous, subcutaneous insulin infusion pump, continuous glucose monitor (CGM), and software, is able to predict changes in blood glucose ...

Absolute incretin effect reduced in type 2 diabetes

June 25, 2012

(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) the absolute incretin effect is reduced compared with healthy individuals, but its relative importance is increased, particularly in first-phase insulin secretion, ...

Recommended for you

Promising progress for new treatment of type 1 diabetes

July 30, 2015

New research from Uppsala University shows promising progress in the use of anti-inflammatory cytokine for treatment of type 1 diabetes. The study, published in the open access journal Scientific Reports, reveals that administration ...

Bacteria may cause type 2 diabetes

June 1, 2015

Bacteria and viruses have an obvious role in causing infectious diseases, but microbes have also been identified as the surprising cause of other illnesses, including cervical cancer (Human papilloma virus) and stomach ulcers ...

'Crosstalk' gives clues to diabetes

June 15, 2015

Sometimes, listening in on a conversation can tell you a lot. For Mark Huising, an assistant professor in the Department of Neurobiology, Physiology and Behavior at the UC Davis College of Biological Sciences, that crosstalk ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.